Patent US5028594A successfully refreshed from Google Patents.
US5028594A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of photodynamic compositions for cytotoxic effects
Assignee: Naxcor Inc
•
Filing: 1988-12-27
•
Granted: 1991-07-02
•
Expires: 2008-12-27
Abstract
Abstract Hematopoietic cells are selectively eliminated by cytotoxic agents which rely upon light activation. The cytotoxic agents are joined to ligands, particularly sugars, specific for myeloid monocyte and lymphocytic lineages. Further specificity can be achieved by limiting the light target. The method and compositions find particular use in organ transplants and arthritis.
Inventors
- 👤 Dennis A. Carson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 05:40
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0057; A61K41/0071
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
69 words
A method for the destruction of hematopoietic cells capable of attacking host cells in vivo, to prevent cellular attack of endogenous cells, said method comprising: contacting cells with a cytotoxic agent comprising a cell-directing ligand specific for binding to said hematopoietic cells, a linking moiety and a photoactivatable toxic component; and, irradiating said cells with light at the appropriate wavelength for a time sufficient to kill said hematopoietic cells.
Claim 2
Independent Claim
69 words
A method for the destruction of hematopoietic cells capable of attacking host cells in vivo, to prevent cellular attack of endogenous cells, said method comprising: contacting cells with a cytotoxic agent comprising a cell-directing ligand specific for binding to said hematopoietic cells, a linking moiety and a photoactivatable toxic component; and, irradiating said cells with light at the appropriate wavelength for a time sufficient to kill said hematopoietic cells.
Claim 3
Dependent Claim
17 words
A method, as recited in claim 1, wherein said cell-directing ligand comprises at least one saccharide monomer.
Claim 4
Dependent Claim
13 words
A method, as recited in claim 2, wherein said saccharide monomer is mannose.
Claim 5
Dependent Claim
17 words
A method, as recited in claim 3, wherein said linking moiety comprises at least one amino acid.
Claim 6
Dependent Claim
13 words
A method, as recited in claim 4, wherein said amino acid is lysine.
Claim 7
Dependent Claim
24 words
A method, as recited in claim 1, wherein said photoactivatable agent is selected from coumarin, psoralens, phthalocyanines, methylene blue, eosin, tetracycline, chlorophyll, and porphyrins.
Claim 8
Dependent Claim
17 words
A method, as recited in claim 1, wherein said cell-directing ligand comprises peptides specific for cytotoxic T-cells.
Claim 9
Dependent Claim
26 words
A method, as recited in claim 1, wherein said hematopoietic cell comprises phagocytes, said linking moiety comprises trilysine, said cell directing ligand comprises four mannose residues.
Claim 10
Dependent Claim
42 words
A method, as recited in claim 1, wherein said hematopoietic cells comprises helper T-cells, said linking moiety comprises a group of about 1 to 60 atoms, other than hydrogen, and said cell directing ligand comprises a peptide ligand specific for cytotoxic T-cells.
Claim 11
Independent Claim
80 words
A method for the selective destruction of hematopoietic cells involved in autoimmune diseases, from a host, said method comprising: contacting said host with a cytotoxic agent comprising a cell-directing ligand specific for binding to said hematopoietic cells, a linking moiety and a photoactivatable toxic component; and, irradiating specific sites of inflammation of said host for a time sufficient to kill said hematopoietic cells at said site, wherein the destruction of host cells away from the site of irradiation is avoided.
Claim 12
Independent Claim
80 words
A method for the selective destruction of hematopoietic cells involved in autoimmune diseases, from a host, said method comprising: contacting said host with a cytotoxic agent comprising a cell-directing ligand specific for binding to said hematopoietic cells, a linking moiety and a photoactivatable toxic component; and, irradiating specific sites of inflammation of said host for a time sufficient to kill said hematopoietic cells at said site, wherein the destruction of host cells away from the site of irradiation is avoided.
Claim 13
Dependent Claim
17 words
A method, as recited in claim 10, wherein said cell-directing ligand comprises at least one saccharide monomer.
Claim 14
Dependent Claim
13 words
A method, as recited in claim 11, wherein said saccharide monomer is mannose.
Claim 15
Dependent Claim
17 words
A method, as recited in claim 10, wherein said cell-directing ligand comprises peptides specific for cytotoxic T-cells.
Claim 16
Dependent Claim
24 words
A method, as recited in claim 10, wherein said photoactivatable agent is selected from coumarin, psoralens, phthalocyanines, methylene blue, eosin, tetracycline, chlorophyll, and porphyrins.
Claim 17
Dependent Claim
48 words
A method, as recited in claim 10, wherein said contacting step further comprises administering said cytotoxic agent through the vascular system of a patient and said irradiating step further comprises directing optical fibers or irradiation lasers to a treatment site for the selective removal of said hematopoietic cells.
Claim 18
Dependent Claim
39 words
A method, as recited in claim 10, wherein said contacting step further comprises injecting said cytotoxic agent directly into a site to be treated and said irradiating step further comprises directing optical fibers or irradiation lasers to said site.
Claim 19
Independent Claim
55 words
A method for removing phagocytic cells from tissue for transplanting comprising contacting said tissue with a cytotoxic agent comprising a specific cell directing ligand specific for binding to said phagocytic cells, a linking moiety and a toxic component specific for the inhibition of DNA replication wherein said cell-directing ligand comprises at least one saccharide monomer.
Claim 20
Independent Claim
55 words
A method for removing phagocytic cells from tissue for transplanting comprising contacting said tissue with a cytotoxic agent comprising a specific cell directing ligand specific for binding to said phagocytic cells, a linking moiety and a toxic component specific for the inhibition of DNA replication wherein said cell-directing ligand comprises at least one saccharide monomer.
Claim 21
Dependent Claim
40 words
A method, as recited in claim 17, wherein said cell directing ligand comprises at least one mannose monomer, said linking moiety comprises at least one amino acid and said toxic component is selected from anthracyclines, amino-acridine derivatives and cis-platinum derivatives.
Claim 22
Dependent Claim
23 words
A method, as recited in claim 17, wherein said tissue is selected from the group consisting of heart, kidneys, liver, lung, and pancreas.
Claim 23
Dependent Claim
31 words
A method, as recited in claim 17, wherein said contacting step further comprises the addition of said cytotoxic agent to a perfusion medium used to maintain said tissue prior to transplantation.
Claim 24
Dependent Claim
42 words
A cytotoxic agent comprising a cell-directing ligand specific for binding to hematopoietic cells, a linking moiety and a toxic component which results in cytotoxicity upon exposure to light in the appropriate wavelength, wherein said cell-directing ligand comprises at least one saccharide monomer.
Claim 25
Dependent Claim
42 words
A cytotoxic agent comprising a cell-directing ligand specific for binding to hematopoietic cells, a linking moiety and a toxic component which results in cytotoxicity upon exposure to light in the appropriate wavelength, wherein said cell-directing ligand comprises at least one saccharide monomer.
Claim 26
Dependent Claim
14 words
A cytotoxic agent, as recited in claim 21, wherein said saccharide monomer is mannose.
Claim 27
Dependent Claim
18 words
A cytotoxic agent, as recited in claim 22, wherein said linking moiety comprises at least one amino acid.
Claim 28
Dependent Claim
14 words
A cytotoxic agent, as recited in claim 23, wherein said amino acid is lysine.
Claim 29
Dependent Claim
27 words
A cytotoxic agent, as recited in claim 24, wherein said photoactivatable agent is selected from coumarin, coumarin derivatives, psoralens, phthalocyanines, methylene blue, eosin, tetracycline, chlorophyll, and porphorins.
Claim 30
Dependent Claim
26 words
A cytotoxic agent, as recited in claim 21, wherein said hematopoietic cell comprises phagocytes, said linking moiety comprises trilysine, said cell directing ligand comprises a tetramannose.
Claim 31
Dependent Claim
39 words
A cytotoxic agent, as recited in claim 21, wherein said hematopoietic cells comprises helper T-cells, said linking moiety comprises a small molecule of about 1 to 60 atoms, said cell directing ligand comprises a peptide specific for cytotoxic T-cells.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-01 | 1994-12-31 | 1995-07-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-01 | 1998-12-31 | 1999-07-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-01 | 2002-12-31 | 2003-07-02 | $7700.00 | Window Closed / Lapsed |